Texas Hospital Indemnity: A Closer Look at New Product Filings
Texas is the leading state for individual health insurance premium volume according to NAIC-compiled annual statement data, making it a natural starting point for anyone looking to understand the Hospital Indemnity product landscape. The Texas Department of Insurance (TDI) maintains publicly available records of insurance product filings through SERFF (System for Electronic Rate and Form Filing), and that database offers a detailed window into what carriers are actually bringing to market. We recently reviewed 36 approved individual Hospital Indemnity policy filings from Texas SERFF, spanning 2023 through mid-2026 and covering 19 different insurance carriers. Here is what we found.
Disclosure Refilings vs. New Products
A notable feature of this filing set is that nearly half of the filings — 17 of 36 — are compliance refilings rather than new product introductions. These carriers were adding the federally required consumer notice mandated by the 2024 Tri-Agency Rule (45 CFR §148.220), which requires fixed indemnity products to carry specific language informing consumers that the coverage is not comprehensive health insurance. In reviewing each of these filings, none contained substantive benefit changes beyond the required disclosure language — they are housekeeping filings, not new product activity.
That leaves 19 filings representing genuine new product activity — new designs, new benefit packages, and in one case a substantive revision. Those are the focus of the observations below.
The Core Benefit Is Universal. What Surrounds It Varies.
Every one of the 19 new products includes the hospital confinement daily benefit — that is the product class's defining feature. But the similarity largely ends there. The secondary benefits included, and whether they appear in the base policy or as optional riders, vary significantly from carrier to carrier. Among the more commonly included secondary benefits in this group:
Ambulance: 14 of 19 products (74%) — more often a rider than a base benefit
Emergency room: 13 of 19 (68%)
Outpatient surgery: 13 of 19 (68%)
Observation unit: 12 of 19 (63%)
Hospital admission lump sum: 11 of 19 (58%)
Mental health inpatient: 11 of 19 (58%)
SNF / extended care: 11 of 19 (58%)
Observation unit coverage stands out. It appears in nearly two-thirds of new products — a meaningfully higher rate than in older products in the broader filing set, where observation coverage was far less common. Given the ongoing trend toward outpatient classification for patients who might previously have been formally admitted, this benefit addresses a real and growing coverage gap. Products that still lack it may be leaving a visible hole in their coverage story.
Cancer lump sum riders appear in 7 of 19 products — always as an optional rider, never built into the base policy. Pet boarding indemnity, which pays a fixed daily benefit toward boarding costs while the insured is hospitalized, appears in 5 of 19 filings. This is a genuinely new benefit category for this product class, and several carriers are clearly using it as a differentiator.
Two Tiers: Budget and Comprehensive
Of the 19 new product filings, 10 included a stated average annual premium in their actuarial materials. That group spans a remarkable range: from $352 to $3,500 per year. Products at opposite ends of that range are substantially different in design — and not just in price.
Products in the $350–$700 range tend to share a set of design characteristics. Daily benefit amounts are lower, the initial benefit period is shorter (often one to five days), and optional riders are fewer. Some are deliberately streamlined: one or two core benefit types, designed to be easy to explain, quote, and administer. The coverage story is straightforward — help offset the cost of a hospital stay without a complicated benefit menu.
Products priced above $1,000 are structurally different. One product in this range stacks nine optional riders, including imaging, prescription drug, SNF, rehabilitation, cancer lump sum, and ambulance. Another uses a unique three-year step-up design where benefit amounts increase automatically in years two and three — a structure more common in life insurance, and the only such design in this filing set. At the high end of the range, one product pairs a streamlined benefit menu with high daily amounts, while another supports a broad rider menu with a richer base policy.
The gap between these tiers reflects genuinely different market segments. The budget tier competes on simplicity and affordability; the comprehensive tier competes on benefit breadth and positions itself closer to gap insurance. Both are approved as individual Hospital Indemnity products under the same Texas regulatory framework.
Underwriting: Differences Across Price Tiers
Underwriting rigor broadly tracks the budget/comprehensive divide, and the most extensive screening in the filing set sits at the high end of the premium range. Applications across the 19 products average 8.1 health questions, ranging from zero to fifteen. One product priced near the top of the range screens for 40+ specifically named conditions across 11 questions — a condition list that runs to cancer, heart disease, stroke, diabetes, COPD, multiple sclerosis, ALS, lupus, rheumatoid arthritis, kidney and liver disease, bipolar disorder, PTSD, drug and alcohol dependency, and more, with a five-year lookback for most. That level of granularity exceeds the condition lists used by every other product in this filing set. The product with the highest question count (15) is also among the highest in premium.
Guaranteed Issue availability is not exclusive to the budget tier. Two lower-premium products offer a GI option for applicants in a specific age range. The conditions most universally screened for across all underwritten products are heart disease/stroke, AIDS/HIV, pending tests or surgery, and prior hospitalization — each asked in 84% of underwritten products. Cancer follows at 79%. Autoimmune conditions (lupus, rheumatoid arthritis, and similar) appear on only 37% of applications despite rising treatment costs, suggesting this may be an area where carriers revisit their criteria in future filings. Three of the 19 products offer a household or cohabitant premium discount — a feature borrowed from life and long-term care insurance that is beginning to appear in this market. One additional product offers a non-tobacco discount, the only pricing distinction of that type in the filing set.
Senior-Focused Products and Age-Based Underwriting
Several products in this filing set are designed with older applicants specifically in mind. One is explicitly labeled as a senior product, with an issue age range of 50 to 85. Another includes a dedicated plan option for applicants age 65 and older, with Guaranteed Issue available for that age band.
Age-based underwriting flexibility is actually quite common across the broader filing set: several products allow applicants above age 64 to skip one or more sections of the health questionnaire when applying for the base policy only (without optional riders). This reduced-question pathway for older applicants is counterintuitive at first glance, but makes sense in context — these products are often positioned alongside Medicare coverage, where the carrier accepts that buyers will have more health history, and speeds enrollment for a population that may otherwise find a long questionnaire discouraging.
One product in this set is guaranteed renewable for life; another is only guaranteed renewable to age 70 — the shortest coverage duration of any filing reviewed, and a meaningful distinction for applicants who may need coverage well beyond that age.
What to Watch
The concentration of new product filings in 2024 — 11 of the 19 — reflects a competitive market with many carriers actively entering or refreshing their Texas portfolios. As this market continues to grow, expect further bifurcation between simple budget designs and comprehensive products that compete on features with gap insurance. Observation unit coverage is a useful illustration of how competitive pressure normalizes benefits over time: once a differentiator, it is now approaching standard in new product designs. Pet boarding may follow a similar path.
We will continue to monitor Hospital Indemnity product filings as new designs emerge.
